Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same author

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

The American journal of gastroenterology·2026
Same author

Patient Experience, Gender, Age, Race, and Social Determinants of Health.

Gastroenterology·2026
Same author

Fear, Feeding, and the Gut: Nutrition Support Considerations in Adults with ARFID and Gastrointestinal Symptoms.

Nutrients·2026
Same author

Short bowel syndrome-associated intestinal failure: diagnosis and prognosis.

Expert review of gastroenterology & hepatology·2026
Same author

Gastric Emptying, Colon Filling, and Multiregional Gut Transit Delays Are Prevalent on Glucagon-Like Peptide-1 Agonists.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?

Expert opinion on emerging drugs·2026
Same journal

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same journal

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same journal

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.

Expert opinion on emerging drugs·2026
Same journal

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Expert opinion on emerging drugs·2026
Same journal

Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.

Expert opinion on emerging drugs·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Emerging drugs for chronic constipation.

Michael D Crowell1, Lucinda A Harris, Tisha N Lunsford

  • 1Mayo Clinic, Mayo Clinic College of Medicine, Division of Gastroenterology, Scottsdale, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA. Crowell.Michael@mayo.edu

Expert Opinion on Emerging Drugs
|August 5, 2009
PubMed
Summary
This summary is machine-generated.

Chronic constipation (CC) affects many, impacting quality of life and healthcare costs. This review examines current and novel therapies for CC, exploring their safety and effectiveness.

Related Experiment Videos

Last Updated: Jun 21, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
03:50

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Area of Science:

  • Gastroenterology
  • Neurogastroenterology
  • Pharmacology

Background:

  • Chronic constipation (CC) is a prevalent functional gastrointestinal disorder affecting up to 27% of North Americans.
  • CC significantly diminishes quality of life and imposes substantial direct and indirect healthcare costs.
  • Etiologies are multifactorial, involving gastrointestinal motility and secretion, neurobiological factors, and pelvic floor dysfunction.

Purpose of the Study:

  • To review the safety and efficacy of established and novel therapeutic approaches for chronic constipation.
  • To provide an overview of the current understanding of CC pathophysiology.
  • To synthesize information on treatment options for clinicians and researchers.

Main Methods:

  • Literature review of traditional and emerging therapies for CC.
  • Analysis of safety and efficacy data from clinical studies and research.
  • Synthesis of information on the multifactorial etiologies of CC.

Main Results:

  • Traditional therapies offer varying degrees of relief but often have limitations.
  • Emerging therapies show promise in addressing specific pathophysiological mechanisms.
  • A comprehensive understanding of CC etiology is crucial for effective treatment selection.

Conclusions:

  • A range of therapeutic options exist for CC, with ongoing research into novel treatments.
  • Personalized treatment strategies based on individual patient factors and CC etiology are essential.
  • Further research is needed to optimize the safety and efficacy of CC therapies.